Metabolomic Profiling of Tyrosine Kinase Inhibitor-Induced Endothelial Dysfunction and Cardiovascular Toxicity
Authors:
- Gurkaranvir SinghGSGurkaranvir Singh
- Inderjeet BharajInderjeet Bharaj
- Joey BettencourtJBJoey Bettencourt
- Amarjit Kaur SekhonASAmarjit Kaur Sekhon
- Gurparvesh SinghGSGurparvesh Singh
- Aaron SidhuASAaron Sidhu
- Emanuel Zayas DiazEmanuel Zayas Diaz
- Sulaiman PaikaSPSulaiman Paika
- Ariel De LeonALAriel De Leon
- Ajit BrarAjit Brar
- Gursimran BrarGBGursimran Brar
- Inderbir PaddaIPInderbir Padda
Open Access
- 17 March 2026
- journal article
- review article
- Published by MDPI AG in Metabolites
- Vol. 16 (3) , 200
Abstract
Background: Tyrosine kinase inhibitors (TKIs) have transformed cancer therapy; however, they are associated with cardiovascular toxicity. Metabolomics provides a comprehensive framework for identifying early biochemical disruptions that precede clinical manifestations and for formulating mechanism-based intervention strategies. Methods: We conducted a narrative synthesis of published preclinical and translational studies on TKI cardiotoxicity, focusing on untargeted and targeted metabolomic findings and complementary proteomic and transcriptomic data. Functional validation was performed using rodent and cellular models. Mechanistic themes were identified, and implications for biomarker panels, multi-omic integration, and metabolomics-guided interventions were proposed. Conclusions: Metabolomic analyses of various TKIs identified convergent signatures along three interconnected axes: (1) mitochondrial bioenergetic dysfunction characterized by impaired long-chain fatty acid oxidation and adenylate depletion; (2) disruption of endothelial nitric oxide signaling with redox imbalance, including increased nitrotyrosine, Nox activation, and eNOS uncoupling; and (3) an inflammatory metabolic profile marked by elevated branched-chain and aromatic amino acids, creatine, and osmolytes. Rodent models of sunitinib and sorafenib replicate these signatures and demonstrate histological injury, contractile dysfunction, and fibrosis. Preclinical intervention data, particularly restoration of myocardial carnitine, AMPK signaling, and fatty acid oxidation by L-carnitine, provide proof of concept for metabolomics-guided cardioprotection. Metabolomics can identify mechanistic biomarkers that facilitate the early detection, risk stratification, and targeted prevention of TKI-induced cardiovascular injury. Translation into precision cardio-oncology requires prospective validation, standardized assays, and biomarker-driven interventional trials.Keywords
This publication has 101 references indexed in Scilit:
- Assessment of Tyrosine Kinase Inhibitors and Survival and Cardiovascular Outcomes of Patients With Non–Small Cell Lung Cancer in TaiwanJAMA Network Open, 2023
- Intracellular Cardiac Signaling Pathways Altered by Cancer Therapies2022
- Increased bleeding risk associated with concurrent vascular endothelial growth factor receptor tyrosine kinase inhibitors and low‐molecular‐weight heparinCancer, 2020
- Risk of QTc prolongation among cancer patients treated with tyrosine kinase inhibitorsInternational Journal of Cancer, 2020
- Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology SocietyEuropean Journal of Heart Failure, 2020
- Simplified plasma essential amino acid-based profiling provides metabolic information and prognostic value additive to traditional risk factors in heart failureAmino Acids, 2018
- Risk of venous and arterial thromboembolic events associated with VEGFR-TKIs: a meta-analysisCancer Chemotherapy and Pharmacology, 2017
- Heart failure associated with sunitinib malateCancer, 2008
- Mass spectrometry‐based metabolomicsMass Spectrometry Reviews, 2006
- Angiogenesis and signal transduction in endothelial cellsCellular and Molecular Life Sciences, 2004